Several reports on tau distribution in MCI subtypes have been published in recent years (Okamura et al., 2015), with tau PET studies using [18F]THK5317 and [18F]AV-1451 showing that tau PET tracers can help distinguish patients with mild cognitive impairment from normal controls, with the topography of tau PET retention including [18F]THK5351 in MCI patients being generally similar across the tau PET tracers used (Chiotis et al., 2016; Cho et al., 2016; Johnson et al., 2016). The gene discussed is MAPT; the disease is Cognitive impairment.